# Module 7B: Host Fibroinflammatory Conditioning Before Regenerative Reconstruction or Transplantation - Evidence Consolidation and Consensus Readiness

## Overview

This tracker records the post-saturation phase for Module 7A. Module 7B converts the frozen Module 7A host-conditioning corpus into atomic observations, author claims, evidence links, boundary conditions, and consensus-ready profiles.

**Boundary condition**: Module 7B may prepare consensus profiles, but project-level `Consensus` records should only be created after observations and author claims are linked to source evidence. Full SQL materialization should wait until first-pass evidence links are complete and low-confidence abstract/source-page rows are upgraded where needed.

**Input corpus**: Module 7A saturation corpus, 40 paper rows plus 8 review/map anchors.

**Module 7 first-pass curation freeze**: 2026-07-16. Status: Module 7A corpus is saturated/frozen first pass; Module 7B evidence consolidation is consensus-ready first pass.

---

## Module 7B Goals

| Goal ID | Goal | Output Table / Artifact | Status |
|---|---|---|---|
| M7B-G001 | Extract atomic empirical observations from Module 7A experiments | Observation | COMPLETE FIRST PASS |
| M7B-G002 | Extract author interpretations separately from observations | AuthorClaim | COMPLETE FIRST PASS |
| M7B-G003 | Link each claim to supporting or contradicting observations | EvidenceLink | COMPLETE FIRST PASS |
| M7B-G004 | Cluster evidence by host-conditioning precedent field and remodeling phase | Consensus-ready evidence profiles | COMPLETE FIRST PASS |
| M7B-G005 | Mark route, timing, host-versus-graft, endpoint, and translation boundaries | Boundary / contradiction map | COMPLETE FIRST PASS |
| M7B-G006 | Draft consensus statements only after linked evidence exists | Consensus | CONSENSUS-READY FIRST PASS |

---

## Evidence Topic Map

| Topic ID | Consensus-Ready Topic | Primary Papers | Evidence Need | Status |
|---|---|---|---|---|
| M7B-T001 | Breast implant capsular contracture is the strongest direct host-conditioning precedent | M7A-P001-P009, P038-P040 | Preserve prophylaxis versus treatment, systemic versus local/transdermal route, and capsule endpoint | CONSENSUS-READY FIRST PASS |
| M7B-T002 | Flap and ischemic-tissue conditioning supports vascular host preparation more than anti-fibrotic remodeling | M7A-P010-P014 | Extract timing, remote/systemic method, angiogenesis, survival, and fibrosis-endpoint absence | CONSENSUS-READY FIRST PASS |
| M7B-T003 | Islet transplantation supports peri-transplant control of IBMIR, macrophage activation, chemokine recruitment, and regulatory transition | M7A-P015-P027 | Separate engraftment, survival, inflammation, macrophage, complement/coagulation, and Treg endpoints | CONSENSUS-READY FIRST PASS |
| M7B-T004 | Organ-tolerance evidence is useful but often rejection-heavy and remodeling-light | M7A-P028-P029 | Preserve rejection versus remodeling endpoint boundary | CONSENSUS-READY FIRST PASS |
| M7B-T005 | SCI leukotriene and resolution studies are lesion-bed conditioning analogs, not direct reconstructive surgery evidence | M7A-P030-P035 | Extract inflammatory timing, functional recovery, neuroprotection, and co-therapy boundaries | CONSENSUS-READY FIRST PASS |
| M7B-T006 | Scar/wound tranilast evidence informs matrix maturation but is route-limited | M7A-P036-P037 | Preserve local/topical delivery and non-implant reconstruction boundary | CONSENSUS-READY FIRST PASS |
| M7B-T007 | Cross-field synthesis requires strict host-target, route, timing, and endpoint ontology | M7A-P001-P040 | Separate systemic host conditioning from donor/graft/local delivery and rejection-only studies | CONSENSUS-READY FIRST PASS |
| M7B-T008 | Module 7B confidence is limited by abstract/source-page extraction and cross-field translation | M7A-P001-P040, M7A-R001-R008 | Preserve confidence labels and field/procedure boundaries | CONSENSUS-READY FIRST PASS |

---

## Pass 4: Observation Extraction Tracker

| Topic ID | Paper ID | Experiment IDs | Target Observation Types | Status | Notes |
|---|---|---|---|---|---|
| M7B-T001 | M7A-P001-P009, P038-P040 | implant capsule rows | leukotriene, pirfenidone, tranilast, tamoxifen, prophylaxis, recurrence, capsule fibrosis | COMPLETE FIRST PASS | Strongest direct precedent |
| M7B-T002 | M7A-P010-P014 | flap conditioning rows | remote ischemic conditioning, systemic preconditioning, HIF, p38, survival, angiogenesis | COMPLETE FIRST PASS | Mostly vascular endpoints |
| M7B-T003 | M7A-P015-P027 | islet transplant rows | IBMIR, A1AT, sulfated dextran, C5a, chemokines, macrophage depletion, Tregs | COMPLETE FIRST PASS | Engraftment not fibrosis |
| M7B-T004 | M7A-P028-P029 | organ tolerance rows | dendritic cells, tolerance induction, chronic rejection | COMPLETE FIRST PASS | Rejection-heavy evidence |
| M7B-T005 | M7A-P030-P035 | SCI rows | leukotriene inhibition, BLT1, zafirlukast, zileuton, resolvins, function | COMPLETE FIRST PASS | Lesion-bed analogy only |
| M7B-T006 | M7A-P036-P037 | scar rows | tranilast, scar cosmesis, hypertrophic scar, local route | COMPLETE FIRST PASS | Matrix maturation boundary |
| M7B-T007 | M7A-P001-P040 | all rows | host/graft target, route, timing, endpoint ontology | COMPLETE FIRST PASS | Cross-field synthesis control |
| M7B-T008 | M7A-R001-R008 and low-confidence rows | review and confidence rows | source confidence, translation limits, full-text upgrade needs | COMPLETE FIRST PASS | Prevents overclaiming |

---

## Pass 4A: Atomic Observations Extracted

| Observation ID | Topic ID | Paper ID | Experiment ID | Figure Ref | Evidence Type | Outcome Type | Observation Value | Normalized Value | Unit | Quantitative | Statistics Reported | Source Section | Extraction Confidence | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M7B-O001 | M7B-T001 | M7A-P001 | M7A-P001-E001 | Abstract | Clinical implant treatment | Capsular contracture | Zafirlukast was reported to reduce capsular contracture in a preliminary breast implant clinical report. | zafirlukast may reduce implant capsule contracture | Baker grade/contracture | YES | abstract-level | Abstract | low | Preliminary clinical precedent. |
| M7B-O002 | M7B-T001 | M7A-P002 | M7A-P002-E001 | Abstract | Anti-fibrotic implant intervention | Capsule fibrosis | Pirfenidone prevented capsular contracture after mammary implantation. | pirfenidone reduces mammary implant capsule fibrosis | capsule/contracture | YES | abstract-level | Abstract | low | Anti-fibrotic anchor. |
| M7B-O003 | M7B-T001 | M7A-P003 | M7A-P003-E001 | Abstract | Clinical anti-fibrotic trial | Established capsular contracture | Pirfenidone was tested clinically for capsular contracture with TGF-beta polymorphism association analysis. | pirfenidone clinical capsule treatment tested | contracture/TGF-beta context | YES | abstract-level | Abstract | low | Treatment rather than prophylaxis. |
| M7B-O004 | M7B-T001 | M7A-P004 | M7A-P004-E001 | Abstract/source page | Prophylactic implant conditioning | Capsule thickness/fibrosis | Cromolyn, montelukast, and zafirlukast prophylaxis were compared for capsular contracture prevention. | leukotriene/mast-cell prophylaxis tested for capsule prevention | capsule thickness/fibrosis | YES | source-page level | Abstract/source page | low | Direct prophylaxis framing. |
| M7B-O005 | M7B-T001 | M7A-P005 | M7A-P005-E001 | Source page | Prophylactic implant conditioning | Capsular contracture | Follow-up literature supported capsule prophylaxis as a recurring construct for cromolyn, montelukast, and zafirlukast. | capsule prophylaxis construct repeated in implant literature | contracture | YES | source-page level | Source page | low | Commentary/follow-up row. |
| M7B-O006 | M7B-T001 | M7A-P006 | M7A-P006-E001 | Abstract/source page | Recurrence prevention | Recurrent capsular contracture | Leukotriene inhibitors were studied for prevention of recurrent capsular contracture in secondary breast augmentation. | leukotriene inhibitors studied for recurrent capsule prevention | recurrence | YES | source-page level | Abstract/source page | medium | Clinical recurrence anchor. |
| M7B-O007 | M7B-T001 | M7A-P007 | M7A-P007-E001 | Abstract/source page | Prophylactic implant model | Capsule formation/fibrosis | Montelukast and tranilast were compared as prophylactic capsule-modifying agents in an alloplastic breast surgery mouse model. | montelukast/tranilast prophylaxis modifies implant capsule biology | capsule formation | YES | source-page level | Abstract/source page | medium | Direct host-conditioning comparison. |
| M7B-O008 | M7B-T001 | M7A-P008 | M7A-P008-E001 | Abstract/source page | Anti-estrogen implant model | Capsule formation | Tamoxifen reduced silicone implant capsule formation in a mouse model. | tamoxifen reduces silicone implant capsule formation | capsule formation | YES | source-page level | Abstract/source page | medium | Systemic/host endocrine boundary. |
| M7B-O009 | M7B-T001 | M7A-P009 | M7A-P009-E001 | Abstract/source page | Transdermal implant model | Capsular contracture | Transdermal tamoxifen improved capsular contracture outcomes in murine breast implantation. | transdermal tamoxifen improves capsule outcome | capsular contracture | YES | source-page level | Abstract/source page | medium | Recipient-directed but route-limited. |
| M7B-O010 | M7B-T002 | M7A-P010 | M7A-P010-E001 | Abstract | Innate immune preconditioning | Ischemic tissue survival | Monophosphoryl lipid A preconditioning improved survival of critically ischemic tissue. | innate preconditioning improves ischemic tissue survival | survival | YES | abstract-level | Abstract | low | Flap survival analog. |
| M7B-O011 | M7B-T002 | M7A-P011 | M7A-P011-E001 | Abstract | Remote ischemic preconditioning | Flap stress signaling | Remote ischemic preconditioning modulated p38 MAP kinase in rat adipocutaneous flaps. | remote preconditioning alters flap stress signaling | p38 signaling | YES | abstract-level | Abstract | low | Mechanistic vascular row. |
| M7B-O012 | M7B-T002 | M7A-P012 | M7A-P012-E001 | Abstract/source page | Systemic pharmacologic preconditioning | Flap necrosis and angiogenic host cells | Systemic prolyl hydroxylase inhibitor preconditioning prevented skin flap necrosis via HIF-1-induced bone marrow-derived cells. | systemic HIF preconditioning reduces flap necrosis | necrosis/host cells | YES | source-page level | Abstract/source page | medium | Strong host-cell mobilization anchor. |
| M7B-O013 | M7B-T002 | M7A-P013 | M7A-P013-E001 | Abstract | Remote ischemic preconditioning | Flap survival/clamping | Remote ischemic preconditioning was tested for rat dorsal skin flap value across clamping time. | remote preconditioning tested for flap survival timing | flap survival | YES | abstract-level | Abstract | low | Timing boundary. |
| M7B-O014 | M7B-T002 | M7A-P014 | M7A-P014-E001 | Abstract | Human reconstructive trial | Free flap reconstruction | A randomized trial tested remote ischemic preconditioning in head and neck cancer reconstruction. | remote preconditioning tested in human free-flap reconstruction | trial endpoint | YES | abstract-level | Abstract | low | Human reconstruction anchor. |
| M7B-O015 | M7B-T003 | M7A-P015 | M7A-P015-E001 | Abstract/source page | Islet peri-transplant conditioning | IBMIR and engraftment | Alpha-1 antitrypsin enhanced islet engraftment by suppressing instant blood-mediated inflammatory reaction. | A1AT suppresses IBMIR and improves islet engraftment | IBMIR/engraftment | YES | source-page level | Abstract/source page | medium | Strong cell-transplant anchor. |
| M7B-O016 | M7B-T003 | M7A-P016 | M7A-P016-E001 | Abstract | Islet peri-transplant conditioning | Inflammation and graft survival | Alpha-1 antitrypsin reduced inflammation and enhanced mouse pancreatic islet transplant survival. | A1AT improves islet survival through inflammation reduction | graft survival | YES | abstract-level | Abstract | low | Mouse graft survival. |
| M7B-O017 | M7B-T003 | M7A-P017 | M7A-P017-E001 | Abstract/source page | Macrophage modulation | Macrophage activation and graft survival | Alpha-1 antitrypsin suppressed macrophage activation and promoted islet graft survival after intrahepatic transplantation. | A1AT suppresses macrophage activation and promotes islet survival | macrophage/graft survival | YES | source-page level | Abstract/source page | medium | Immune-stromal transition anchor. |
| M7B-O018 | M7B-T003 | M7A-P018 | M7A-P018-E001 | Abstract/source page | Human islet autotransplant trial | Autologous islet engraftment | A randomized pilot trial tested etanercept and alpha-1 antitrypsin to improve autologous islet engraftment. | anti-inflammatory peri-transplant trial tested in human islet autotransplant | engraftment | YES | source-page level | Abstract/source page | medium | Human trial anchor. |
| M7B-O019 | M7B-T003 | M7A-P019 | M7A-P019-E001 | Abstract/source page | Human TPIAT trial | Islet autotransplant outcomes | Alpha-1 antitrypsin augmentation therapy was tested in chronic pancreatitis patients undergoing total pancreatectomy and islet autotransplantation. | A1AT augmentation tested in TPIAT | islet autotransplant outcome | YES | source-page level | Abstract/source page | medium | Human RCT anchor. |
| M7B-O020 | M7B-T003 | M7A-P020 | M7A-P020-E001 | Abstract/source page | Human islet autotransplant follow-up | Long-term diabetes outcomes | Peri-transplant inflammation and long-term diabetes outcomes were not improved by etanercept or alpha-1 antitrypsin in a follow-up analysis. | A1AT/etanercept benefit not confirmed in long-term islet autotransplant outcomes | diabetes outcome/inflammation | YES | source-page level | Abstract/source page | medium | Contradiction boundary. |
| M7B-O021 | M7B-T003 | M7A-P021 | M7A-P021-E001 | Abstract/source page | Islet transplant IBMIR modulation | Safety/efficacy and IBMIR-related outcomes | Low molecular weight sulfated dextran was evaluated for safety and efficacy in islet transplantation. | sulfated dextran tested as IBMIR-related islet conditioning | safety/efficacy | YES | source-page level | Abstract/source page | medium | Complement/coagulation-adjacent. |
| M7B-O022 | M7B-T003 | M7A-P022 | M7A-P022-E001 | Abstract | Complement inhibition | Inflammatory mediator induction | C5a inhibitory peptide was analyzed for inflammatory mediators induced after islet transplantation. | C5a inhibition targets early islet inflammatory mediators | inflammatory mediators | YES | abstract-level | Abstract | low | Complement phase 1. |
| M7B-O023 | M7B-T003 | M7A-P023 | M7A-P023-E001 | Abstract/source page | Chemokine blockade | Engraftment and graft survival | CCL2/MCP-1 and CXCL12/SDF-1 blockade improved pancreatic islet engraftment and survival in mouse. | chemokine blockade improves islet engraftment/survival | engraftment/survival | YES | source-page level | Abstract/source page | medium | Monocyte recruitment axis. |
| M7B-O024 | M7B-T003 | M7A-P024 | M7A-P024-E001 | Abstract | Macrophage depletion | Graft survival and microenvironment activation | Macrophage depletion altered graft survival and microenvironment activation after allogeneic islet transplantation. | macrophages shape islet graft microenvironment and survival | graft survival/microenvironment | YES | abstract-level | Abstract | low | Direction needs full text. |
| M7B-O025 | M7B-T003 | M7A-P025 | M7A-P025-E001 | Abstract/source page | Regulatory immune induction | Tregs, tolerogenic dendritic cells, engraftment | Apoptotic cell administration enhanced islet engraftment by inducing Tregs and tolerogenic dendritic cells. | apoptotic cell host conditioning induces Tregs/DCs and improves engraftment | Tregs/DCs/engraftment | YES | source-page level | Abstract/source page | medium | Immune transition anchor. |
| M7B-O026 | M7B-T003 | M7A-P026 | M7A-P026-E001 | Abstract | Treg expansion | Long-term islet graft survival | Endogenous expansion of regulatory T cells led to long-term islet graft survival in diabetic NOD mice. | Treg expansion supports long-term islet graft survival | graft survival | YES | abstract-level | Abstract | low | Regulatory host state. |
| M7B-O027 | M7B-T003 | M7A-P027 | M7A-P027-E001 | Abstract/source page | Tolerogenic microparticles | Islet engraftment | Immunomodulating tolerogenic microparticles improved islet engrafts via Treg induction. | tolerogenic microparticles induce Tregs and improve islet engraftment | engraftment | YES | source-page level | Abstract/source page | medium | Biomaterial but host-directed. |
| M7B-O028 | M7B-T004 | M7A-P028 | M7A-P028-E001 | Abstract/source page | Organ tolerance | Alloimmune rejection | Circular RNA FSCN1-silenced dendritic cells prevented alloimmune rejection in heart transplantation. | tolerogenic dendritic cell strategy prevents rejection | rejection | YES | source-page level | Abstract/source page | medium | Remodeling endpoint unclear. |
| M7B-O029 | M7B-T004 | M7A-P029 | M7A-P029-E001 | Abstract | Chronic rejection model | Tolerance induction | A second renal allograft model analyzed mechanisms of tolerance induction in chronic rejection. | renal allograft tolerance model informs chronic rejection boundary | tolerance/rejection | YES | abstract-level | Abstract | low | Rejection-heavy boundary. |
| M7B-O030 | M7B-T005 | M7A-P030 | M7A-P030-E001 | Abstract/source page | SCI leukotriene inhibition | Inflammation and functional outcome | Zileuton and montelukast were tested for effects in mouse experimental SCI. | leukotriene inhibitors tested after SCI | inflammation/function | YES | source-page level | Abstract/source page | medium | SCI lesion-bed analog. |
| M7B-O031 | M7B-T005 | M7A-P031 | M7A-P031-E001 | Abstract/source page | SCI leukotriene axis | Neutrophil infiltration and secondary injury | LTB4-BLT1 mediated neutrophil infiltration and secondary injury after experimental SCI. | LTB4-BLT1 drives neutrophil-linked secondary SCI injury | neutrophil/secondary injury | YES | source-page level | Abstract/source page | medium | Phase 1 inflammatory amplification. |
| M7B-O032 | M7B-T005 | M7A-P032 | M7A-P032-E001 | Abstract/source page | SCI combination therapy | Injury attenuation and motor function | Zafirlukast plus pseudohypericin attenuated SCI and motor dysfunction in mice. | zafirlukast combination attenuates SCI motor dysfunction | motor function | YES | source-page level | Abstract/source page | low | Combination boundary. |
| M7B-O033 | M7B-T005 | M7A-P033 | M7A-P033-E001 | Abstract | SCI zileuton treatment | Ferroptosis and functional recovery | Zileuton ameliorated neuronal ferroptosis and functional recovery after SCI. | zileuton improves ferroptosis/recovery endpoints after SCI | ferroptosis/function | YES | abstract-level | Abstract | low | Recent low-confidence row. |
| M7B-O034 | M7B-T005 | M7A-P034 | M7A-P034-E001 | Abstract/source page | SCI resolution biology | Resolution, neuroprotection, functional recovery | Resolvin D3 promoted inflammatory resolution, neuroprotection, and functional recovery after SCI. | resolvin D3 promotes resolution and recovery after SCI | resolution/function | YES | source-page level | Abstract/source page | medium | Pro-resolving anchor. |
| M7B-O035 | M7B-T005 | M7A-P035 | M7A-P035-E001 | Abstract/source page | SCI co-therapy | Repair and functional outcome | Resolvin D1 co-administered with peripheral nerve-derived stem cell spheroids was tested as SCI therapy. | resolvin D1 co-therapy tested with cell spheroids | repair/function | YES | source-page level | Abstract/source page | medium | Not pure host conditioning. |
| M7B-O036 | M7B-T006 | M7A-P036 | M7A-P036-E001 | Abstract | Human scar treatment | Scar cosmesis | Tranilast liposomal gel was tested against placebo for post-cesarean scar outcome. | topical tranilast affects surgical scar outcome | scar cosmesis | YES | abstract-level | Abstract | low | Local-route boundary. |
| M7B-O037 | M7B-T006 | M7A-P037 | M7A-P037-E001 | Abstract | Hypertrophic scar model | Hypertrophic scar/fibrosis | Tranilast-loaded microneedles were tested for hypertrophic scar treatment in rabbits. | local tranilast delivery targets hypertrophic scar fibrosis | scar/fibrosis | YES | abstract-level | Abstract | low | Local delivery, not systemic. |
| M7B-O038 | M7B-T001 | M7A-P038 | M7A-P038-E001 | Review/source | Implant capsule synthesis | Capsule contracture outcomes | A systematic review mapped non-surgical treatment and prophylaxis of mammary implant capsular contracture. | implant capsule prophylaxis/treatment literature exists as synthesis base | review synthesis | YES | review-level | Review/source | medium | Review anchor. |
| M7B-O039 | M7B-T001 | M7A-P039 | M7A-P039-E001 | Review/source | Leukotriene antagonist synthesis | Capsule contracture outcomes | A systematic review/meta-analysis evaluated leukotriene receptor antagonists for capsular contracture prevention/treatment. | LTRA capsule evidence has meta-analytic synthesis | meta-analysis | YES | review-level | Review/source | medium | Review anchor. |
| M7B-O040 | M7B-T001 | M7A-P040 | M7A-P040-E001 | Review/source | Leukotriene antagonist synthesis | Capsule contracture outcomes | A meta-analysis evaluated leukotriene receptor antagonists for periprosthetic capsular contracture treatment and prevention. | LTRA capsule prevention/treatment has prior meta-analysis | meta-analysis | YES | review-level | Review/source | medium | Review anchor. |

---

## Pass 5: Author Claim Extraction Tracker

| Topic ID | Paper ID | Claim Types To Extract | Status |
|---|---|---|---|
| M7B-T001 | M7A-P001-P009, P038-P040 | implant prophylaxis; anti-fibrotic/leukotriene/tamoxifen effects; treatment versus prevention | COMPLETE FIRST PASS |
| M7B-T002 | M7A-P010-P014 | vascular preconditioning; flap survival; angiogenesis; fibrosis endpoint limits | COMPLETE FIRST PASS |
| M7B-T003 | M7A-P015-P027 | islet engraftment; IBMIR; complement/coagulation; macrophage/chemokine/Treg conditioning | COMPLETE FIRST PASS |
| M7B-T004 | M7A-P028-P029 | organ tolerance; rejection boundary | COMPLETE FIRST PASS |
| M7B-T005 | M7A-P030-P035 | SCI inflammatory lesion-bed analog; leukotriene and resolution pathways | COMPLETE FIRST PASS |
| M7B-T006 | M7A-P036-P037 | scar/matrix maturation; local route limits | COMPLETE FIRST PASS |
| M7B-T007 | M7A-P001-P040 | host/graft distinction; timing/route/endpoint ontology | COMPLETE FIRST PASS |
| M7B-T008 | M7A-R001-R008 | confidence and translation limits | COMPLETE FIRST PASS |

---

## Pass 5A: Author Claims Extracted

| Claim ID | Topic ID | Paper ID | Claim Text | Claim Type | Confidence Level | Source Section | Extraction Confidence | Notes |
|---|---|---|---|---|---|---|---|---|
| M7B-C001 | M7B-T001 | M7A-P001, P004-P007, P038-P040 | Leukotriene receptor antagonism is a recurring host-conditioning strategy for breast implant capsular contracture prevention or treatment. | synthesis | high | Tracker/review map | medium | Strongest Module 7 precedent. |
| M7B-C002 | M7B-T001 | M7A-P002-P003 | Pirfenidone provides anti-fibrotic capsule evidence in mammary implant models and clinical capsular contracture treatment. | conclusion | medium | Abstract | low | Treatment/prophylaxis distinction needed. |
| M7B-C003 | M7B-T001 | M7A-P007 | Tranilast is represented as a prophylactic capsule-modifying comparator in implant models. | conclusion | medium | Abstract/source page | medium | Mostly preclinical in tracker. |
| M7B-C004 | M7B-T001 | M7A-P008-P009 | Tamoxifen can reduce silicone implant capsule formation or capsular contracture outcomes in mouse/murine models. | conclusion | medium | Abstract/source page | medium | Route differs across rows. |
| M7B-C005 | M7B-T001 | M7A-P001-P009 | Breast implant capsule evidence should distinguish prophylaxis, recurrence prevention, and treatment of established contracture. | boundary condition | high | Module 7A tracker | high | Timing boundary. |
| M7B-C006 | M7B-T002 | M7A-P010-P014 | Flap preconditioning evidence supports the idea that recipient/systemic state can be modified before tissue transfer. | conclusion | medium | Abstract/source page | low | Vascular endpoints dominate. |
| M7B-C007 | M7B-T002 | M7A-P012 | Systemic hypoxia-pathway preconditioning can mobilize host bone marrow-derived mechanisms and reduce skin flap necrosis. | conclusion | medium | Abstract/source page | medium | Strongest flap host-cell row. |
| M7B-C008 | M7B-T002 | M7A-P010-P014 | Flap preconditioning should not be overread as anti-fibrotic conditioning unless remodeling endpoints are measured. | boundary condition | high | Module 7A tracker | high | Endpoint boundary. |
| M7B-C009 | M7B-T003 | M7A-P015-P020 | Alpha-1 antitrypsin and related peri-transplant anti-inflammatory strategies can target early islet engraftment barriers, but human follow-up evidence is mixed. | synthesis | high | Abstract/source page | medium | Includes neutral follow-up. |
| M7B-C010 | M7B-T003 | M7A-P015, P021-P022 | IBMIR/complement/coagulation-adjacent pathways are early host-response targets in islet transplantation. | conclusion | medium | Abstract/source page | medium | Phase 1 transplant analog. |
| M7B-C011 | M7B-T003 | M7A-P017, P023-P024 | Macrophage and chemokine recruitment pathways shape islet graft survival and microenvironment activation. | conclusion | medium | Abstract/source page | medium | Immune-stromal transition. |
| M7B-C012 | M7B-T003 | M7A-P025-P027 | Regulatory immune conditioning through Tregs and tolerogenic dendritic-cell programs can improve islet engraftment or survival in preclinical settings. | conclusion | medium | Abstract/source page | medium | Biomaterial-host boundary for P027. |
| M7B-C013 | M7B-T003 | M7A-P015-P027 | Islet evidence is primarily engraftment/survival evidence and should not be treated as direct anti-fibrotic reconstruction evidence. | boundary condition | high | Module 7A tracker | high | Endpoint boundary. |
| M7B-C014 | M7B-T004 | M7A-P028-P029 | Organ-tolerance studies can inform host immune conditioning but are often rejection-centered rather than remodeling-centered. | boundary condition | high | Module 7A tracker | high | Rejection-only caution. |
| M7B-C015 | M7B-T005 | M7A-P030-P033 | Leukotriene pathway inhibition after SCI can reduce secondary injury-associated processes and improve functional endpoints in animal models. | conclusion | medium | Abstract/source page | medium | Lesion-bed analog. |
| M7B-C016 | M7B-T005 | M7A-P031 | LTB4-BLT1 signaling links leukotriene biology to neutrophil infiltration and secondary SCI injury. | mechanistic | medium | Abstract/source page | medium | Phase 1 amplification. |
| M7B-C017 | M7B-T005 | M7A-P034-P035 | Pro-resolving lipid mediator strategies can improve inflammatory resolution and recovery-associated endpoints after SCI, but co-therapy rows need attribution boundaries. | synthesis | medium | Abstract/source page | medium | D1 spheroid co-therapy boundary. |
| M7B-C018 | M7B-T005 | M7A-P030-P035 | SCI leukotriene/resolution evidence should be treated as lesion-bed conditioning analogy rather than direct preoperative reconstruction evidence. | boundary condition | high | Module 7A tracker | high | Translation boundary. |
| M7B-C019 | M7B-T006 | M7A-P036-P037 | Tranilast scar studies support matrix-maturation biology but are mainly local/topical route evidence in this corpus. | boundary condition | high | Abstract | low | Not systemic host conditioning. |
| M7B-C020 | M7B-T007 | M7A-P001-P040 | Module 7 synthesis must preserve whether the intervention targets the recipient host, graft/donor, scaffold/local depot, or transplanted cells. | synthesis | high | Module 7A tracker | high | Central ontology claim. |
| M7B-C021 | M7B-T007 | M7A-P001-P040 | Route is a first-class variable because oral/systemic, transdermal, remote ischemic, biologic, local depot, and co-therapy interventions imply different host-conditioning strength. | synthesis | high | Module 7A tracker | high | Route ontology. |
| M7B-C022 | M7B-T007 | M7A-P001-P040 | Timing is a first-class variable because prophylaxis, perioperative conditioning, post-injury treatment, chronic treatment, and recurrence prevention are not interchangeable. | synthesis | high | Module 7A tracker | high | Timing ontology. |
| M7B-C023 | M7B-T007 | M7A-P001-P040 | Remodeling endpoints must be kept separate from survival, rejection, function, and engraftment endpoints. | synthesis | high | Module 7A tracker | high | Endpoint ontology. |
| M7B-C024 | M7B-T008 | M7A-P001-P040 | Most Module 7B rows are abstract/source-page level and should remain confidence-limited until full text confirms dose, route, timing, and endpoint details. | boundary condition | high | Module 7A tracker | high | Evidence-quality boundary. |
| M7B-C025 | M7B-T008 | M7A-R001-R008 | Cross-field evidence is hypothesis-generating for SCI reconstruction unless direct SCI reconstructive conditioning studies are available. | synthesis | high | Review map | medium | Translation boundary. |
| M7B-C026 | M7B-T001 | M7A-P038-P040 | Review/meta-analysis rows support the existence of an implant prophylaxis literature but should not replace extraction from primary intervention studies. | boundary condition | high | Review/source | medium | Review boundary. |
| M7B-C027 | M7B-T003 | M7A-P020 | Neutral or negative islet autotransplant follow-up data should be retained as a contradiction to simple anti-inflammatory benefit claims. | boundary condition | high | Abstract/source page | medium | Important contradiction. |
| M7B-C028 | M7B-T002 | M7A-P014 | Human reconstructive preconditioning evidence exists but is thin in this first-pass corpus. | boundary condition | medium | Abstract | low | Human flap RCT anchor. |
| M7B-C029 | M7B-T001 | M7A-P006 | Recurrence-prevention studies are closest to perioperative reconstruction conditioning but still may involve patients with prior capsule biology. | boundary condition | medium | Abstract/source page | medium | Recurrence boundary. |
| M7B-C030 | M7B-T005 | M7A-P030-P035 | Early SCI anti-inflammatory or pro-resolving treatment may be relevant to future graft-bed preparation hypotheses. | implication | medium | Module 7A tracker | medium | Not direct reconstruction. |
| M7B-C031 | M7B-T003 | M7A-P027 | Biomaterial-delivered tolerogenic microparticles should be classified as host-directed immunomodulation only when the recipient immune response is the target endpoint. | boundary condition | high | Abstract/source page | medium | Local/scaffold nuance. |
| M7B-C032 | M7B-T006 | M7A-P036-P037 | Local scar studies are useful for Phase 4 matrix maturation but should be excluded from systemic-host-conditioning consensus claims. | boundary condition | high | Module 7A tracker | high | Local route. |
| M7B-C033 | M7B-T001 | M7A-P001, P006, P039-P040 | Leukotriene antagonist implant evidence is triangulated across clinical reports, recurrence-prevention studies, and reviews, but agent, dose, indication, and evidence-quality boundaries remain important. | synthesis | high | Abstract/source page and review map | medium | Keeps LTRA claim strong but bounded. |
| M7B-C034 | M7B-T002 | M7A-P012, P014 | Flap preconditioning includes a mechanistic host-cell mobilization signal and at least one human reconstruction trial, but the corpus remains thin for remodeling-specific endpoints. | synthesis | medium | Abstract/source page | medium | Completes human/flap boundary. |
| M7B-C035 | M7B-T003 | M7A-P018-P020 | Human islet autotransplant studies show that peri-transplant anti-inflammatory conditioning can be tested clinically, but early engraftment rationale may not translate into durable diabetes-outcome benefit. | boundary condition | high | Abstract/source page | medium | Strengthens contradiction handling. |
| M7B-C036 | M7B-T007 | M7A-P001-P040 | Module 7 evidence should be graded by directness for SCI reconstruction: direct reconstructive/implant conditioning, transplant engraftment conditioning, SCI lesion-bed analogs, and local scar biology are different evidence tiers. | synthesis | high | Module 7A tracker | high | Evidence-tier ontology. |

---

## Pass 6: Evidence Links Drafted

| Link ID | Claim ID | Observation ID | Link Type | Strength | Notes |
|---|---|---|---|---|---|
| M7B-L001 | M7B-C001 | M7B-O001 | supports | low | Zafirlukast clinical row |
| M7B-L002 | M7B-C001 | M7B-O004 | supports | low | LTRA prophylaxis comparison |
| M7B-L003 | M7B-C001 | M7B-O006 | supports | medium | Recurrence prevention |
| M7B-L004 | M7B-C001 | M7B-O039 | contextual_support | medium | LTRA review/meta-analysis |
| M7B-L005 | M7B-C001 | M7B-O040 | contextual_support | medium | LTRA meta-analysis |
| M7B-L006 | M7B-C002 | M7B-O002 | supports | low | Pirfenidone prevention |
| M7B-L007 | M7B-C002 | M7B-O003 | supports | low | Pirfenidone clinical treatment |
| M7B-L008 | M7B-C003 | M7B-O007 | supports | medium | Tranilast comparator |
| M7B-L009 | M7B-C004 | M7B-O008 | supports | medium | Tamoxifen mouse implant |
| M7B-L010 | M7B-C004 | M7B-O009 | supports | medium | Transdermal tamoxifen |
| M7B-L011 | M7B-C005 | M7B-O001 | contextual_support | low | Treatment/prevention ambiguity |
| M7B-L012 | M7B-C005 | M7B-O003 | contextual_support | low | Established contracture treatment |
| M7B-L013 | M7B-C005 | M7B-O004 | contextual_support | low | Prophylaxis |
| M7B-L014 | M7B-C005 | M7B-O006 | contextual_support | medium | Recurrence prevention |
| M7B-L015 | M7B-C006 | M7B-O010 | supports | low | Innate preconditioning |
| M7B-L016 | M7B-C006 | M7B-O011 | supports | low | Remote ischemic signaling |
| M7B-L017 | M7B-C006 | M7B-O012 | supports | medium | Systemic HIF preconditioning |
| M7B-L018 | M7B-C006 | M7B-O014 | contextual_support | low | Human free-flap RCT |
| M7B-L019 | M7B-C007 | M7B-O012 | supports | medium | Host-cell mobilization |
| M7B-L020 | M7B-C008 | M7B-O010 | contextual_support | low | Survival endpoint |
| M7B-L021 | M7B-C008 | M7B-O013 | contextual_support | low | Flap timing/survival |
| M7B-L022 | M7B-C008 | M7B-O014 | contextual_support | low | Reconstruction trial endpoint unspecified |
| M7B-L023 | M7B-C009 | M7B-O015 | supports | medium | A1AT IBMIR |
| M7B-L024 | M7B-C009 | M7B-O016 | supports | low | Mouse survival |
| M7B-L025 | M7B-C009 | M7B-O017 | supports | medium | Macrophage activation |
| M7B-L026 | M7B-C009 | M7B-O018 | supports | medium | Human pilot trial |
| M7B-L027 | M7B-C009 | M7B-O019 | supports | medium | Human RCT test |
| M7B-L028 | M7B-C009 | M7B-O020 | contradicts | medium | Follow-up neutral outcome |
| M7B-L029 | M7B-C010 | M7B-O015 | supports | medium | IBMIR A1AT |
| M7B-L030 | M7B-C010 | M7B-O021 | supports | medium | Sulfated dextran |
| M7B-L031 | M7B-C010 | M7B-O022 | supports | low | C5a inhibition |
| M7B-L032 | M7B-C011 | M7B-O017 | supports | medium | Macrophage activation |
| M7B-L033 | M7B-C011 | M7B-O023 | supports | medium | Chemokine blockade |
| M7B-L034 | M7B-C011 | M7B-O024 | supports | low | Macrophage depletion |
| M7B-L035 | M7B-C012 | M7B-O025 | supports | medium | Apoptotic cell/Treg/DC |
| M7B-L036 | M7B-C012 | M7B-O026 | supports | low | Treg expansion |
| M7B-L037 | M7B-C012 | M7B-O027 | supports | medium | Tolerogenic microparticles |
| M7B-L038 | M7B-C013 | M7B-O015 | contextual_support | medium | Engraftment endpoint |
| M7B-L039 | M7B-C013 | M7B-O020 | contextual_support | medium | Diabetes outcome endpoint |
| M7B-L040 | M7B-C013 | M7B-O023 | contextual_support | medium | Survival endpoint |
| M7B-L041 | M7B-C014 | M7B-O028 | supports | medium | Rejection-centered heart transplant |
| M7B-L042 | M7B-C014 | M7B-O029 | supports | low | Chronic rejection/tolerance |
| M7B-L043 | M7B-C015 | M7B-O030 | supports | medium | Zileuton/montelukast SCI |
| M7B-L044 | M7B-C015 | M7B-O032 | contextual_support | low | Zafirlukast combo SCI |
| M7B-L045 | M7B-C015 | M7B-O033 | contextual_support | low | Zileuton ferroptosis |
| M7B-L046 | M7B-C016 | M7B-O031 | supports | medium | LTB4-BLT1 neutrophils |
| M7B-L047 | M7B-C017 | M7B-O034 | supports | medium | Resolvin D3 |
| M7B-L048 | M7B-C017 | M7B-O035 | contextual_support | medium | Resolvin D1 co-therapy |
| M7B-L049 | M7B-C018 | M7B-O030 | supports | high | SCI not reconstruction |
| M7B-L050 | M7B-C018 | M7B-O035 | supports | high | Co-therapy/SCI boundary |
| M7B-L051 | M7B-C019 | M7B-O036 | supports | low | Topical tranilast |
| M7B-L052 | M7B-C019 | M7B-O037 | supports | low | Microneedle tranilast |
| M7B-L053 | M7B-C020 | M7B-O027 | contextual_support | medium | Biomaterial but host-directed |
| M7B-L054 | M7B-C020 | M7B-O035 | contextual_support | medium | Cell co-therapy |
| M7B-L055 | M7B-C021 | M7B-O009 | contextual_support | medium | Transdermal route |
| M7B-L056 | M7B-C021 | M7B-O012 | contextual_support | medium | Systemic route |
| M7B-L057 | M7B-C021 | M7B-O036 | contextual_support | low | Local route |
| M7B-L058 | M7B-C022 | M7B-O004 | contextual_support | low | Prophylaxis |
| M7B-L059 | M7B-C022 | M7B-O006 | contextual_support | medium | Recurrence prevention |
| M7B-L060 | M7B-C022 | M7B-O030 | contextual_support | medium | Post-injury treatment |
| M7B-L061 | M7B-C023 | M7B-O010 | contextual_support | low | Survival endpoint |
| M7B-L062 | M7B-C023 | M7B-O015 | contextual_support | medium | Engraftment endpoint |
| M7B-L063 | M7B-C023 | M7B-O028 | contextual_support | medium | Rejection endpoint |
| M7B-L064 | M7B-C024 | M7B-O001 | supports | high | Low-confidence example |
| M7B-L065 | M7B-C024 | M7B-O033 | supports | high | Abstract-level recent row |
| M7B-L066 | M7B-C025 | M7B-O014 | contextual_support | low | Human reconstruction but vascular |
| M7B-L067 | M7B-C025 | M7B-O030 | contextual_support | medium | SCI analogy |
| M7B-L068 | M7B-C026 | M7B-O038 | supports | medium | Review synthesis |
| M7B-L069 | M7B-C026 | M7B-O039 | supports | medium | Review/meta-analysis |
| M7B-L070 | M7B-C026 | M7B-O040 | supports | medium | Review/meta-analysis |
| M7B-L071 | M7B-C027 | M7B-O020 | supports | medium | Neutral/negative follow-up |
| M7B-L072 | M7B-C028 | M7B-O014 | supports | low | Human flap RCT |
| M7B-L073 | M7B-C029 | M7B-O006 | supports | medium | Recurrence prevention |
| M7B-L074 | M7B-C030 | M7B-O030 | supports | medium | Leukotriene SCI |
| M7B-L075 | M7B-C030 | M7B-O034 | supports | medium | Resolvin SCI |
| M7B-L076 | M7B-C031 | M7B-O027 | supports | medium | Tolerogenic microparticle endpoint |
| M7B-L077 | M7B-C032 | M7B-O036 | supports | low | Local scar gel |
| M7B-L078 | M7B-C032 | M7B-O037 | supports | low | Local scar microneedle |
| M7B-L079 | M7B-C033 | M7B-O001 | supports | low | Clinical zafirlukast evidence |
| M7B-L080 | M7B-C033 | M7B-O006 | supports | medium | Recurrence prevention evidence |
| M7B-L081 | M7B-C033 | M7B-O039 | contextual_support | medium | Review/meta-analysis evidence |
| M7B-L082 | M7B-C034 | M7B-O012 | supports | medium | Host-cell mobilization signal |
| M7B-L083 | M7B-C034 | M7B-O014 | supports | low | Human reconstruction trial anchor |
| M7B-L084 | M7B-C035 | M7B-O018 | contextual_support | medium | Human anti-inflammatory trial |
| M7B-L085 | M7B-C035 | M7B-O020 | contradicts_simple_benefit | medium | Neutral/negative long-term outcome |
| M7B-L086 | M7B-C036 | M7B-O038 | contextual_support | medium | Direct implant reconstruction tier |
| M7B-L087 | M7B-C036 | M7B-O015 | contextual_support | medium | Transplant engraftment tier |
| M7B-L088 | M7B-C036 | M7B-O030 | contextual_support | medium | SCI lesion-bed analog tier |

---

## Boundary Conditions Draft

| Boundary ID | Boundary Statement | Evidence Scope | Handling in Consensus | Status |
|---|---|---|---|---|
| M7B-B001 | Host conditioning is distinct from donor organ conditioning, ex vivo graft/cell preconditioning, and scaffold-local drug delivery. | M7B-O001-O040; M7B-C020-C021, C031-C032 | Consensus must specify target and route. | COMPLETE FIRST PASS |
| M7B-B002 | Breast implant capsular contracture is the strongest direct precedent, but implant capsule biology should not be directly equated with SCI graft-bed biology. | M7B-O001-O009, O038-O040; M7B-C001-C005, C026, C029 | Translate as precedent, not as SCI proof. | COMPLETE FIRST PASS |
| M7B-B003 | Flap preconditioning evidence is mostly vascular/ischemia-reperfusion evidence rather than explicit anti-fibrotic remodeling evidence. | M7B-O010-O014; M7B-C006-C008, C028 | Label as vascular host preparation. | COMPLETE FIRST PASS |
| M7B-B004 | Islet transplantation evidence often measures engraftment, IBMIR, macrophage activation, and survival rather than fibrosis or tissue architecture. | M7B-O015-O027; M7B-C009-C013, C027, C031 | Keep endpoint labels precise. | COMPLETE FIRST PASS |
| M7B-B005 | Organ transplantation rows are often rejection-centered and should not be included in remodeling consensus unless remodeling/integration outcomes are explicit. | M7B-O028-O029; M7B-C014 | Rejection-only evidence is boundary evidence. | COMPLETE FIRST PASS |
| M7B-B006 | SCI leukotriene/resolution rows are lesion-bed conditioning analogs rather than direct preoperative reconstructive-surgery evidence. | M7B-O030-O035; M7B-C015-C018, C030 | Use as SCI plausibility evidence only. | COMPLETE FIRST PASS |
| M7B-B007 | Local scar or local-depot rows inform matrix biology but should not support systemic host-conditioning statements. | M7B-O009, O027, O036-O037; M7B-C019, C021, C031-C032 | Route must be explicit. | COMPLETE FIRST PASS |
| M7B-B008 | Perioperative timing categories are non-equivalent: prophylaxis, perioperative treatment, post-injury treatment, chronic treatment, and recurrence prevention must remain distinct. | M7B-O001-O040; M7B-C005, C022, C029 | Consensus must state timing window. | COMPLETE FIRST PASS |

---

## Consensus Draft Queue

| Consensus Draft ID | Topic ID | Draft Statement | Supporting Observations | Supporting Claims | Boundary Records | Source Agreement Label | Status |
|---|---|---|---|---|---|---|---|
| M7B-S001 | M7B-T001 | Breast implant capsular contracture provides the strongest direct precedent that recipient-directed pharmacologic conditioning can alter fibrotic capsule outcomes, especially through leukotriene antagonists and anti-fibrotic or anti-estrogen strategies. | M7B-O001-O009, O038-O040 | M7B-C001-C005, C026, C029, C033 | M7B-B001-B002, M7B-B007-B008 | moderate | CONSENSUS-READY FIRST PASS |
| M7B-S002 | M7B-T002 | Flap and ischemic-tissue studies show that recipient or remote systemic preconditioning can improve vascular survival biology before tissue transfer, but this is not yet equivalent to anti-fibrotic recipient-bed conditioning. | M7B-O010-O014 | M7B-C006-C008, C028, C034 | M7B-B003, M7B-B008 | mixed | CONSENSUS-READY FIRST PASS |
| M7B-S003 | M7B-T003 | Islet transplantation supports peri-transplant host conditioning as a strategy to reduce early inflammatory engraftment barriers, including IBMIR, complement/coagulation signaling, macrophage activation, chemokine recruitment, and regulatory immune balance. | M7B-O015-O027 | M7B-C009-C013, C027, C031, C035 | M7B-B004, M7B-B007-B008 | mixed | CONSENSUS-READY FIRST PASS |
| M7B-S004 | M7B-T004 | Organ tolerance studies are useful for the host-conditioning concept but should remain boundary evidence unless rejection control is linked to remodeling, vascular integration, fibrosis, or functional graft integration. | M7B-O028-O029 | M7B-C014 | M7B-B005 | low/mixed | CONSENSUS-READY FIRST PASS |
| M7B-S005 | M7B-T005 | SCI leukotriene and pro-resolving mediator studies support the plausibility that early fibroinflammatory lesion-bed state can be modified, but they are analogs rather than direct preoperative reconstruction studies. | M7B-O030-O035 | M7B-C015-C018, C030 | M7B-B006, M7B-B008 | moderate | CONSENSUS-READY FIRST PASS |
| M7B-S006 | M7B-T006 | Tranilast scar and hypertrophic-scar studies inform matrix-maturation biology, but local or topical delivery rows should not be used as evidence for systemic host conditioning. | M7B-O036-O037 | M7B-C019, C032 | M7B-B007 | low | CONSENSUS-READY FIRST PASS |
| M7B-S007 | M7B-T007 | Module 7 host-conditioning synthesis requires an explicit ontology for intervention target, route, timing, procedure class, endpoint, and evidence directness, because the corpus spans systemic drugs, remote ischemic conditioning, local delivery, immune-cell modulation, and co-therapy. | M7B-O001-O040 | M7B-C020-C023, C031-C032, C036 | M7B-B001-B008 | high on method, mixed on biology | CONSENSUS-READY FIRST PASS |
| M7B-S008 | M7B-T008 | Cross-field host-conditioning evidence is hypothesis-generating for SCI reconstruction and should remain confidence-stratified until full-text extraction confirms dose, route, timing, host target, and remodeling endpoint. | M7B-O001-O040 | M7B-C024-C025 | M7B-B001-B008 | high on method, mixed on biology | CONSENSUS-READY FIRST PASS |

---

## Module 7B Completion Checklist

| Requirement | Status | Notes |
|---|---|---|
| Atomic observations extracted before consensus drafting | MET FOR ALL FIRST-PASS TOPICS | 40 observation rows |
| Author claims separated from observations | MET FOR ALL FIRST-PASS TOPICS | 36 claim rows |
| Claims linked to observations | MET FOR ALL FIRST-PASS TOPICS | 88 evidence links |
| Boundaries and contradictions recorded | MET FOR ALL FIRST-PASS TOPICS | 8 boundary records |
| Consensus statements drafted only after linked evidence exists | MET FOR ALL FIRST-PASS TOPICS | 8 consensus-ready statements |
| Confidence labels retained | MET FOR ALL FIRST-PASS TOPICS | Most rows remain low or medium confidence |
